In vitro activity of tigecycline and comparators (2014 –2016) among key WHO ‘priority pathogens’ and longitudinal assessment (2004–2016) of antimicrobial resistance – a report from the T.E.S.T. study

The World Health Organization (WHO) recently published a list of antimicrobial-resistant ‘priority pathogens’ that pose a major threat to public health. The list aims to guide and promote research and development of new antimicrobials to help tackle global antimicrobial resistance [1]. The global increase in resistance is a major public health crisis threatening the delivery of heal thcare and patient safety [2]. Resistance to antimicrobials such as the carbapenems is of particular concern as this leaves few treatment alternatives for patients with severe infections caused by resistant pathogens, and may result in increased hospital admissions, prolonged length of stay and incr eased mortality [2–6].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research